Back to Market返回行情

CDIO Cardio Diagnostics Holdings, Inc.

USHealthcare
$1.84-0.54%OpenMarket Cap: $3.8M

As of 2026-07-10 14:43

Why CDIO matters now

Cardio Diagnostics Holdings, Inc. (CDIO) is a US stock in Healthcare. The latest InvestLog snapshot shows $1.84 with -0.54% on the session and $3.8M in market capitalization; recent performance reads 1-month +44.53% and YTD -26.94%.

The latest financial table shown here is Q1 2026, with revenue of $2.7K, net income of $-1.8M, and EPS of $-0.63. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -148.5%.

The latest indexable market news headline is "Atlas Healthcare Physicians to Cover Cardio Diagnostics' Precision Cardiovascular Medicine Tests Across Its Network" from Business Wire.

Additional event context on this page matters because analyst consensus is Buy with a median target of $—; recent insider activity includes Burton Paul Frederick filing A-Award. These signals are research inputs, not a recommendation.

Valuation

P/E (TTM)

PEG

P/B

0.63

P/S

247.50

EV/EBITDA

0.39

DCF Value

$2.23

FCF Yield

-148.5%

Div Yield

0.0%

Margins & Returns

Gross Margin

-471.4%

Operating Margin

-40074.6%

Net Margin

-40152.5%

ROE

-78.8%

ROA

-69.6%

ROIC

-70.3%

Financials

PeriodRevenueNet IncomeEPS
Q1 2026$2.7K$-1.8M$-0.63
Q4 2025$3.6K$-1.5M$-0.80
FY 2025$14.8K$-6.5M$-3.71
Q3 2025$2.9K$-1.7M$-0.98

Analyst Ratings

Consensus

Buy

Target (Consensus)

$—

Target (Median)

$—

Target Range

$— - $—

Strong Buy: 0Buy: 1Hold: 0Sell: 0Strong Sell: 0

Trading Activity

Insider Trades

Burton Paul Frederickdirector
Sell2026-04-02
Intrater Jamesdirector
Sell2026-04-02
Betts Wendy Jdirector
Sell2026-04-02
Fung Peter Kdirector
Sell2026-04-02
Burton Paul Frederickdirector
Sell2026-01-06

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

US

Exchange

Beta

2.20

Cardio Diagnostics Holdings, Inc. specializes in creating and bringing to market advanced clinical diagnostic tools that leverage epigenetic insights to address cardiovascular disease. Among their key offerings is Epi+Gen CHD, a test designed to assess an individual's three-year risk for developing symptomatic coronary heart disease. This company, headquartered in Chicago, Illinois, was established in 2017.